OncoCyte Past Earnings Performance
Past criteria checks 0/6
OncoCyte's earnings have been declining at an average annual rate of -8.1%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 33% per year.
Key information
-8.1%
Earnings growth rate
13.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 33.0% |
| Return on equity | -33.5% |
| Net Margin | -1,562.0% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How OncoCyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 1 | -17 | 18 | 7 |
| 31 Mar 23 | 1 | -11 | 20 | 7 |
| 31 Dec 22 | 1 | -19 | 22 | 7 |
| 30 Sep 22 | 0 | -30 | 17 | 5 |
| 30 Jun 22 | 0 | -34 | 16 | 3 |
| 31 Mar 22 | 1 | -43 | 19 | 3 |
| 31 Dec 21 | 2 | -44 | 20 | 5 |
| 30 Sep 21 | 5 | -35 | 29 | 10 |
| 30 Jun 21 | 4 | -28 | 26 | 10 |
| 31 Mar 21 | 2 | -26 | 23 | 11 |
| 31 Dec 20 | 1 | -30 | 22 | 9 |
| 30 Sep 20 | 1 | -32 | 22 | 10 |
| 30 Jun 20 | 0 | -30 | 20 | 9 |
| 31 Mar 20 | 0 | -26 | 19 | 8 |
| 31 Dec 19 | 0 | -22 | 15 | 7 |
| 30 Sep 19 | 0 | -19 | 13 | 5 |
| 30 Jun 19 | 0 | -17 | 11 | 6 |
| 31 Mar 19 | 0 | -16 | 9 | 6 |
| 31 Dec 18 | 0 | -16 | 9 | 6 |
| 30 Sep 18 | 0 | -15 | 8 | 7 |
| 30 Jun 18 | 0 | -19 | 12 | 7 |
| 31 Mar 18 | 0 | -18 | 11 | 7 |
| 31 Dec 17 | 0 | -19 | 12 | 7 |
| 30 Sep 17 | 0 | -19 | 11 | 7 |
| 30 Jun 17 | 0 | -14 | 7 | 7 |
| 31 Mar 17 | 0 | -13 | 7 | 6 |
| 31 Dec 16 | 0 | -11 | 5 | 6 |
| 30 Sep 16 | 0 | -12 | 6 | 6 |
| 30 Jun 16 | 0 | -11 | 6 | 5 |
| 31 Mar 16 | 0 | -10 | 5 | 5 |
| 31 Dec 15 | 0 | -9 | 4 | 5 |
| 30 Sep 15 | 0 | -7 | 2 | 4 |
| 30 Jun 15 | 0 | -5 | 1 | 4 |
| 31 Mar 15 | 0 | -5 | 1 | 4 |
| 31 Dec 14 | 0 | -5 | 1 | 4 |
Quality Earnings: 7OC0 is currently unprofitable.
Growing Profit Margin: 7OC0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7OC0 is unprofitable, and losses have increased over the past 5 years at a rate of 8.1% per year.
Accelerating Growth: Unable to compare 7OC0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7OC0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 7OC0 has a negative Return on Equity (-33.54%), as it is currently unprofitable.